Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles

The objective of this study was to confirm that weight loss after treatment with mitratapide (Yarvitan®) is loss of adipose tissue. Obese dogs were treated with the recommended treatment schedule of mitratapide. Dual-energy X-ray absorptiometry (DEXA) was done before and after the treatment schedule...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary research communications 2009-12, Vol.33 (8), p.839-847
Main Authors: Dobenecker, Britta, De Bock, Manuelle, Engelen, Marc, Goossens, Lieve, Scholz, Armin, Kienzle, Ellen
Format: Article
Language:English
Subjects:
Absorptiometry, Photon - veterinary
adipose tissue
Adipose Tissue - drug effects
Animals
Anti-Obesity Agents - pharmacology
Anti-Obesity Agents - therapeutic use
Beagle
Biomedical and Life Sciences
body composition
Body Composition - drug effects
body fat
body measurements
body weight
Body Weight - drug effects
dog diseases
Dog Diseases - drug therapy
Dogs
dual-energy X-ray absorptiometry
Eating - drug effects
enzyme inhibitors
feed intake
Female
glucose tolerance
Glucose Tolerance Test - veterinary
Life Sciences
mitratapide
obesity
Obesity - drug therapy
Obesity - veterinary
Original
Original Article
pelvic circumference
Piperazines - pharmacology
Piperazines - therapeutic use
Triazoles - pharmacology
Triazoles - therapeutic use
veterinary drugs
Veterinary Medicine/Veterinary Science
weight loss
Zoology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to confirm that weight loss after treatment with mitratapide (Yarvitan®) is loss of adipose tissue. Obese dogs were treated with the recommended treatment schedule of mitratapide. Dual-energy X-ray absorptiometry (DEXA) was done before and after the treatment schedule. Body weight, feed consumption and pelvic circumference were recorded and a glucose tolerance test was performed. Dual-energy X-ray absorptiometry measurements showed an impressive loss of fat tissue, corresponding to a mean loss of approximately 41.6% of the body fat mass recorded before treatment. After treatment with mitratapide, the mean body fat percentage had returned within the normal range. At the end of the study, the dogs had lost on average 14.2% of their body weight and 15.2% of their pelvic circumference compared to baseline. The results also suggest that losing weight with mitratapide might help to reverse insulin resistance.
ISSN:0165-7380
1573-7446
DOI:10.1007/s11259-009-9232-5